These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 30257528)

  • 1. Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars.
    Uifălean A; Ilieş M; Nicoară R; Rus LM; Hegheş SC; Iuga CA
    Pharmaceutics; 2018 Sep; 10(4):. PubMed ID: 30257528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
    Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
    Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: controversies as illustrated by rhGH.
    Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
    Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States.
    Miller EM; Schwartzberg LS
    Ther Adv Med Oncol; 2019; 11():1758835919887044. PubMed ID: 31798693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trastuzumab and its biosimilars].
    Sarosiek T; Morawski P
    Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biosimilars in the European Union: current situation and challenges].
    Wolff-Holz E; Weise M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars for breast cancer.
    Migliavacca Zucchetti B; Nicolò E; Curigliano G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1015-1021. PubMed ID: 31248290
    [No Abstract]   [Full Text] [Related]  

  • 16. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worldwide experience with biosimilar development.
    McCamish M; Woollett G
    MAbs; 2011; 3(2):209-17. PubMed ID: 21441787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.